Mixed fortunes as good news follows bad on the rollout of Covid vaccines
A week of distress over the halving of AstraZeneca stocks ended on a brighter note as pharma firms rolled up their sleeves to help in the rollout and new vaccines look set to take up some of the slack
At the end of a difficult week for Europe’s vaccination programme, there was relief in the Department of Health as the AstraZeneca vaccine was approved for all adult age groups by the European Medicines Agency (EMA).
Speaking to the Business Post last Friday, Stephen Donnelly welcomed the approval, but cautioned that lower production from AstraZeneca’s European factories would mean the previously publicised target of vaccinating 700,000 people by the end of March would...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month, €19.99 Monthly thereafter
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
Homeless charity’s frontline staff have yet to get vaccines
Three Alice Leahy Trust workers who provide face-to-face services to homeless people have been waiting eight weeks for their Covid-19 jabs
Analysis: Vaccination effect is evident among older age groups
Despite hiccups in the rollout of the Covid-19 vaccination programme, some 17 per cent of the population have received their first dose
Government rules out foreign holidays in June
Despite plans for EU vaccine passport, Martin and Varadkar say international travel is off the cards for now
Government should begin delayed dosing programme this week, O‘Neill says
If the British 12-week delay strategy were applied to Ireland, it could result in 80 per cent of the adult population being vaccinated with a first dose by the end of May
